BioMarin Pharmaceutical Inc. BMRN

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs despite volatility from a Federal Reserve leadership transition and Middle East tensions. Markets rebounded from Q1 lows, […]

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.

EMERYVILLE, Calif., September 30, 2026--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.9% gain over the past six months, beating the S&P 500 by 25.5 percentage points.

SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a

BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite...

BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.

With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting. The data included new results on the magnitude of benefit seen in children receiving VOXZOGO, including statistically significant improvements in annualized growth ve

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 has gained 13.6%.